Search results for "From ACP Journal Club"
Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo
A review published prior to the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial found that aspirin only reduced cardiovascular events in diabetes patients with pre-existing cardiovascular disease.
https://diabetes.acponline.org/archives/2016/12/09/5.htm
9 Dec 2016
In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years
These long-term follow-up data show no legacy effect from intensive glucose control on cardiovascular (CV) events, differing from the results of the United Kingdom Prospective Diabetes Study, an ACP Journal Club commentary noted.
https://diabetes.acponline.org/archives/2019/10/11/8.htm
11 Oct 2019
In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide
This industry-funded trial of tirzepatide, a unimolecular dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, heralds a new era of “twincretins” in diabetes management, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/11/12/6.htm
12 Nov 2021
Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations
Incretin-based drugs did not appear to be associated with greater heart failure hospitalization risk compared with commonly used combinations of oral antidiabetic drugs, a cohort study found.
https://diabetes.acponline.org/archives/2016/08/12/6.htm
12 Aug 2016
One-step screening approach detected more gestational diabetes than two-step approach but did not improve clinical outcomes
A screening approach that finds more cases of gestational diabetes without improving patient outcomes introduces considerable burden and costs to patients, clinicians, and medical systems, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/08/13/6.htm
13 Aug 2021
Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM
A recent Italian trial showed that regimens with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a sodium-glucose cotransporter 2 (SGLT2) inhibitor resulted in less hypoglycemia, but the results may not apply to patients with higher HbA1c levels, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/09/10/7.htm
10 Sep 2021
In overweight or obese patients with diabetes, a lifestyle intervention increased weight loss at 8 years
Receiving an intensive lifestyle intervention (ILI) rather than traditional diabetes support and education (DSE) increased weight loss in about 5,000 middle-aged adults with type 2 diabetes.
https://diabetes.acponline.org/archives/2014/07/11/5.htm
11 Jul 2014
Review: In patients with type 2 diabetes who fast, sitagliptin reduces hypoglycemia more than sulfonylurea
Patients who took sitagliptin were significantly less likely to have hypoglycemia during Ramadan, according to a systematic review.
https://diabetes.acponline.org/archives/2015/11/13/6.htm
13 Nov 2015
In metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels
Patients whose diabetes was inadequately controlled on metformin showed similar weight loss, improvement in HbA1c, and adverse events whether they took dulaglutide or liraglutide, a trial found.
https://diabetes.acponline.org/archives/2014/12/12/6.htm
12 Dec 2014
In high-risk pregnant women, an individualized lifestyle intervention reduced gestational diabetes mellitus
The intervention in the Finnish study targeted women with previous gestational diabetes mellitus or a body mass index of 30 kg/m2 or greater.
https://diabetes.acponline.org/archives/2016/01/08/5.htm
8 Jan 2016